Ahmed Emam1,2, Gregory Hermann3, Kristopher Attwood4, Wenyan Ji4, Gaybrielle James1, Michael Kuettel3, James L Mohler1. 1. Departments of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. 2. Department of Urology, Ain Shams University, Cairo, Egypt. 3. Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. 4. Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Abstract
OBJECTIVE: To compare the oncologic outcomes of radical prostatectomy (RP) versus external beam radiotherapy (EBRT) ± androgen deprivation therapy for primary treatment of high risk localized prostate cancer (CaP). METHODS: We retrospectively reviewed a prospectively-populated database for cases who underwent primary treatment for high risk localized CaP, had more than 2 years follow-up, and were treated since 2006. A total of 335 cases were studied of whom 291 underwent RP and 44 underwent EBRT. Clinical characteristics, biochemical progression-free survival (BPFS), metastasis-free survival (MFS), cancer-specific survival (CSS) and overall survival (OS) were compared. RESULTS: EBRT cases were older (p < .01; mean 71 years vs. 61 years) and had longer PSA doubling time (PSADT) (p = .03; median 4.8 years vs. 3.5 years) than RP. Race, pretreatment PSA and biopsy Gleason score were similar. Median follow-up was 5.1 (range: 2.3-12.8) years for RP versus 3.3 (range: 2-12.4) years for EBRT. Three- and 5-year BPFS were 42% and 36% after RP versus 86% and 75% after EBRT (p < .01). The rate of adjuvant/salvage therapy was 58% after RP versus 20% after EBRT (p < .01). Three- and 5-year MFS were 80% and 77% after RP versus 91% and 91% after EBRT (p = .11). Three-year CSS was 98% in both groups and OS was 97% after RP versus 94% after EBRT (p = .73). CONCLUSIONS: RP had higher rates of biochemical failure and adjuvant or salvage treatment versus EBRT in high risk localized CaP. MFS trended toward benefit after EBRT, but CSS and OS remained high in both groups.
OBJECTIVE: To compare the oncologic outcomes of radical prostatectomy (RP) versus external beam radiotherapy (EBRT) ± androgen deprivation therapy for primary treatment of high risk localized prostate cancer (CaP). METHODS: We retrospectively reviewed a prospectively-populated database for cases who underwent primary treatment for high risk localized CaP, had more than 2 years follow-up, and were treated since 2006. A total of 335 cases were studied of whom 291 underwent RP and 44 underwent EBRT. Clinical characteristics, biochemical progression-free survival (BPFS), metastasis-free survival (MFS), cancer-specific survival (CSS) and overall survival (OS) were compared. RESULTS: EBRT cases were older (p < .01; mean 71 years vs. 61 years) and had longer PSA doubling time (PSADT) (p = .03; median 4.8 years vs. 3.5 years) than RP. Race, pretreatment PSA and biopsy Gleason score were similar. Median follow-up was 5.1 (range: 2.3-12.8) years for RP versus 3.3 (range: 2-12.4) years for EBRT. Three- and 5-year BPFS were 42% and 36% after RP versus 86% and 75% after EBRT (p < .01). The rate of adjuvant/salvage therapy was 58% after RP versus 20% after EBRT (p < .01). Three- and 5-year MFS were 80% and 77% after RP versus 91% and 91% after EBRT (p = .11). Three-year CSS was 98% in both groups and OS was 97% after RP versus 94% after EBRT (p = .73). CONCLUSIONS: RP had higher rates of biochemical failure and adjuvant or salvage treatment versus EBRT in high risk localized CaP. MFS trended toward benefit after EBRT, but CSS and OS remained high in both groups.
Authors: Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-15 Impact factor: 7.038
Authors: Philip Cornford; Joaquim Bellmunt; Michel Bolla; Erik Briers; Maria De Santis; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Thomas Wiegel; Nicolas Mottet Journal: Eur Urol Date: 2016-08-31 Impact factor: 20.096
Authors: Amar U Kishan; Ryan R Cook; Jay P Ciezki; Ashley E Ross; Mark M Pomerantz; Paul L Nguyen; Talha Shaikh; Phuoc T Tran; Kiri A Sandler; Richard G Stock; Gregory S Merrick; D Jeffrey Demanes; Daniel E Spratt; Eyad I Abu-Isa; Trude B Wedde; Wolfgang Lilleby; Daniel J Krauss; Grace K Shaw; Ridwan Alam; Chandana A Reddy; Andrew J Stephenson; Eric A Klein; Daniel Y Song; Jeffrey J Tosoian; John V Hegde; Sun Mi Yoo; Ryan Fiano; Anthony V D'Amico; Nicholas G Nickols; William J Aronson; Ahmad Sadeghi; Stephen Greco; Curtiland Deville; Todd McNutt; Theodore L DeWeese; Robert E Reiter; Johnathan W Said; Michael L Steinberg; Eric M Horwitz; Patrick A Kupelian; Christopher R King Journal: JAMA Date: 2018-03-06 Impact factor: 56.272
Authors: Steven Joniau; Alberto Briganti; Paolo Gontero; Giorgio Gandaglia; Lorenzo Tosco; Steffen Fieuws; Bertrand Tombal; Giansilvio Marchioro; Jochen Walz; Burkhard Kneitz; Pia Bader; Detlef Frohneberg; Alessandro Tizzani; Markus Graefen; Paul van Cangh; R Jeffrey Karnes; Francesco Montorsi; Hein Van Poppel; Martin Spahn Journal: Eur Urol Date: 2014-01-25 Impact factor: 20.096
Authors: Stephen A Boorjian; R Jeffrey Karnes; Rosalia Viterbo; Laureano J Rangel; Eric J Bergstralh; Eric M Horwitz; Michael L Blute; Mark K Buyyounouski Journal: Cancer Date: 2011-01-10 Impact factor: 6.860
Authors: Michael S Hofman; Nathan Lawrentschuk; Roslyn J Francis; Colin Tang; Ian Vela; Paul Thomas; Natalie Rutherford; Jarad M Martin; Mark Frydenberg; Ramdave Shakher; Lih-Ming Wong; Kim Taubman; Sze Ting Lee; Edward Hsiao; Paul Roach; Michelle Nottage; Ian Kirkwood; Dickon Hayne; Emma Link; Petra Marusic; Anetta Matera; Alan Herschtal; Amir Iravani; Rodney J Hicks; Scott Williams; Declan G Murphy Journal: Lancet Date: 2020-03-22 Impact factor: 79.321
Authors: Benedikt Hoeh; Jan L Hohenhorst; Rocco Flammia; Benedikt Horlemann; Gabriele Sorce; Francesco Chierigo; Zhe Tian; Fred Saad; Markus Graefen; Michele Gallucci; Alberto Briganti; Carlo Terrone; Shahrokh F Shariat; Luis A Kluth; Andreas Becker; Felix K H Chun; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2021-11-16 Impact factor: 2.370